Dario Tumino

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Replacement Therapy

Prognostic Factors

Ejection Fraction

Top Venues

Endocrinology, diabetes & metabolism

Clinical endocrinology

This page only lists publications with an associated author ORCID identifier.

Publications

Antonio Prinzi, Francesco Frasca, Marco Russo, Gabriella Pellegriti, Tommaso Piticchio, Dario Tumino, Ernestina Marianna De Francesco, Pasqualino Malandrino
Pre-Operative Calcitonin and CEA Values May Predict the Extent of Metastases to the Lateral Neck Lymph Nodes in Patients with Medullary Thyroid Cancer. Cancers 16 (17) (2024)
Rosario Le Moli, Pasqualino Malandrino, Marco Russo, Dario Tumino, Tommaso Piticchio, Adriano Naselli, Valentina Rapicavoli, Antonino Belfiore, Francesco Frasca
Levothyroxine therapy, calculated deiodinases activity and basal metabolic rate in obese or nonobese patients after total thyroidectomy for differentiated thyroid cancer, results of a retrospective observational study. Endocrinology, diabetes & metabolism (2023)
Rosario Le Moli, Pasqualino Malandrino, Marco Russo, Dario Tumino, Tommaso Piticchio, Adriano Naselli, Valentina Rapicavoli, Antonino Belfiore, Francesco Frasca
Levothyroxine therapy, calculated deiodinases activity and basal metabolic rate in obese or nonobese patients after total thyroidectomy for differentiated thyroid cancer, results of a retrospective observational study. Endocrinology, diabetes & metabolism 6 (2) (2023)
Rosario Le Moli, Pasqualino Malandrino, Marco Russo, Dario Tumino, Tommaso Piticchio, Adriano Naselli, Valentina Rapicavoli, Antonino Belfiore, Francesco Frasca
Levothyroxine therapy, calculated deiodinases activity and basal metabolic rate in obese or nonobese patients after total thyroidectomy for differentiated thyroid cancer, results of a retrospective observational study. Endocrinology, diabetes & metabolism 6 (2) (2023)
Rosario Le Moli, Pasqualino Malandrino, Marco Russo, Dario Tumino, Tommaso Piticchio, Adriano Naselli, Valentina Rapicavoli, Antonino Belfiore, Francesco Frasca
Levothyroxine therapy, calculated deiodinases activity and basal metabolic rate in obese or nonobese patients after total thyroidectomy for differentiated thyroid cancer, results of a retrospective observational study. Endocrinology, diabetes & metabolism 6 (2) (2023)
Rosario Le Moli, Pasqualino Malandrino, Marco Russo, Dario Tumino, Tommaso Piticchio, Adriano Naselli, Valentina Rapicavoli, Antonino Belfiore, Francesco Frasca
Levothyroxine therapy, calculated deiodinases activity and basal metabolic rate in obese or nonobese patients after total thyroidectomy for differentiated thyroid cancer, results of a retrospective observational study. Endocrinology, diabetes & metabolism 6 (2) (2023)
Rosario Le Moli, Pasqualino Malandrino, Marco Russo, Dario Tumino, Tommaso Piticchio, Adriano Naselli, Valentina Rapicavoli, Antonino Belfiore, Francesco Frasca
Levothyroxine therapy, calculated deiodinases activity and basal metabolic rate in obese or nonobese patients after total thyroidectomy for differentiated thyroid cancer, results of a retrospective observational study. Endocrinology, diabetes & metabolism 6 (2) (2023)
Rosario Le Moli, Pasqualino Malandrino, Marco Russo, Dario Tumino, Tommaso Piticchio, Adriano Naselli, Valentina Rapicavoli, Antonino Belfiore, Francesco Frasca
Levothyroxine therapy, calculated deiodinases activity and basal metabolic rate in obese or nonobese patients after total thyroidectomy for differentiated thyroid cancer, results of a retrospective observational study. Endocrinology, diabetes & metabolism 6 (2) (2023)
Marco Russo, Damiano Gullo, Dario Tumino, Daniela Leonardi, Pasqualino Malandrino, Francesco Frasca
Different FT3/TSH correlation in acquired and congenital hypothyroid patients reveals a different hypothalamic set-point. Clinical endocrinology 98 (1) (2022)
Fiorenza Gianì, Veronica Vella, Dario Tumino, Pasqualino Malandrino, Francesco Frasca
The Possible Role of Cancer Stem Cells in the Resistance to Kinase Inhibitors of Advanced Thyroid Cancer. Cancers 12 (8) (2020)